MSB 4.02% 95.5¢ mesoblast limited

Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-391

  1. 8,933 Posts.
    lightbulb Created with Sketch. 6768
    Yes indeed a very appalling decision from the FDA , they will have to deal with that together with the very serious conflict of interest sooner than you think , while I think the FDA would not have expected this stance from MSB ?I can imagine MSB would have said , sorry we have more pressing and important trials to deal with at this time and that the FDA GVHD decision will have to rest on their heads , its not over yet MSB'ers when the FDA makes a very obvious stupid decision that will kill children with GVHD, heads will roll.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.5¢
Change
-0.040(4.02%)
Mkt cap ! $1.093B
Open High Low Value Volume
$1.00 $1.01 95.0¢ $1.524M 1.564M

Buyers (Bids)

No. Vol. Price($)
17 98720 95.5¢
 

Sellers (Offers)

Price($) Vol. No.
96.0¢ 73326 50
View Market Depth
Last trade - 14.10pm 20/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.